Lakefront Biotherapeutics (GLPGF) Share-based Compensation (2016 - 2020)

Lakefront Biotherapeutics (GLPGF) has reported Share-based Compensation for 5 consecutive years, with $33.5 million the latest figure, recorded in Q2 2020.

• On a quarterly basis, Share-based Compensation rose 177.31% year-over-year to $33.5 million in Q2 2020; TTM through Jun 2020 was $67.6 million, a 79.92% increase from a year earlier, with the FY2025 full-year figure at $27.1 million, up 25.98% from the prior year.
• Share-based Compensation was $33.5 million for Q2 2020 at Lakefront Biotherapeutics, up from $10.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.7 billion in Q2 2017 and troughed at -$8.2 billion in Q3 2017.
• A 5-year average of -$24.1 million and a median of $8.3 million in 2018 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 289559.74% in 2017 and sank 99.9% in 2018, its largest moves.
• Over 5 years, Share-based Compensation stood at $2.6 million in 2016, then surged by 34.63% to $3.6 million in 2017, then soared by 180.78% to $10.0 million in 2018, then grew by 12.63% to $11.3 million in 2019, then surged by 197.62% to $33.5 million in 2020.
• The last three Share-based Compensation figures came in at $33.5 million (Q2 2020), $10.2 million (Q1 2020), and $11.3 million (Q4 2019), per Business Quant data.